alpha-1-antitrypsin deficiency

View All

alpha-1-antitrypsin-deficiency-treatment-market
Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market

In the 21st century, public health has yielded major advances in understanding and managing diseases. Sometimes, early diagnosis remains crucial in managing and treating a serious condition. One such rare genetic disorder, alpha-1 antitrypsin deficiency (AATD), has witnessed improvements concerning awareness and co...

Find More

Pharma News and Updates for Takeda, Gilead, and Odyssey
CHMP Reviews Takeda’s Qdenga; FDA Sets Date for Gilead’ Trodelvy Review; Odyssey’s Announces $ 168 Million Series B Financing; Tavros and Vividion Signs Agreement; Pharming Submits Leniolisib for Approval in the EU; FDA Fast Track Designation to Mereo’s Alvelestat

CHMP Gives Positive Opinion on Takeda’s Qdenga  The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given its approval to Takeda GmbH’s Qdenga, a live, attenuated dengue tetravalent vaccine (TAK-003). It is the first time the CHMP has reviewed a medicinal product ...

Find More

Alpha-1-Antitrypsin-Deficiency-Market-Symptoms-Treatments-Key-Companies
Alpha-1 Antitrypsin Deficiency: Symptoms, Treatments and Key Companies in the Market

Alpha1-antitrypsin deficiency (AATD) was first identified by Carl-Bertil Laurell and Sten Eriksson (Laurell and Eriksson 1963) in 1963,  who discovered a link between low plasma serum AAT levels and pulmonary emphysema symptoms. With time as the understanding of the genetic abnormalities grew, AAT deficiency c...

Find More

Antitrypsin Deficiency Pipeline
Antitrypsin Deficiency Pipeline

Many Pharmaceuticals companies are working across the globe towards the development of new treatment therapies for Alpha-1 Anti-trypsin Deficiency to fulfil the unmet needs of Anti-trypsin Deficiency Therapeutic market as discussed in the previous article. The Alpha-1 Anti-trypsin Deficiency market is expected to c...

Find More

Antitrypsin deficiency
Unmet Needs in the treatment of Antitrypsin deficiency

Antitrypsin deficiency, also called AAT deficiency (Alpha-1 Antitrypsin deficiency) is an inherited disease characterized by severe problems that make difficult to breathe. Along with lung disease, it can also cause serious issues in the liver too. Mutations in the SERPINA1 gene, whose primary function is to transc...

Find More

Delveinsight
DelveInsight’s Respiratory disorders based Gene Therapy Reports

Gene Therapy’s “expanding” role in Respiratory disorders! About Respiratory disorders Respiratory disorders encompasses pathological conditions affecting the organs and tissues that make gas exchange possible in higher organisms, and includes conditions of the upper respiratory tract, trachea, bronchi, bronchioles...

Find More